文献速递特殊人群用药治疗药物监测与药物基因组学

治疗前血浆代谢组学预测白消安清除率

Prediction of Busulfan Clearance by Predose Plasma Metabolomic Profiling.
PubMed 文献 · Clin Pharmacol Ther · 2022-12-26

本研究在132例造血干细胞移植患者中评估治疗前血浆841种内源性代谢物能否预测静脉白消安清除率。单因素分析发现37种代谢物与清除率显著相关,LASSO回归筛选13种构建线性预测模型,在96例提前2周采集的样本中解释40%的清除率变异。作者认为药物代谢组学方法可优先于试验剂量或药物基因组学指导白消安给药。

要点

  • 治疗前血浆13种内源性代谢物线性模型可预测白消安清除率。
  • 该模型在提前2周采集样本中解释40%的白消安清除率变异。
  • 研究者建议药物代谢组学优先于试验剂量或药物基因组学指导给药。

核心结论

  • 白消安清除率可通过治疗前13种内源性代谢物的线性回归模型预测。
  • 药物代谢组学有潜力作为精准医学工具改进或替代药代动力学方法个体化白消安剂量。

研究设计与样本

  • 前瞻性队列研究,纳入132例接受造血干细胞移植并静脉使用白消安的患者。
  • 全部患者在白消安给药前即刻采集样本,其中96例另在给药前2周采集样本。
  • 检测血浆841种内源性代谢物,采用单因素线性回归和LASSO惩罚回归筛选变量并构建预测模型。

主要发现

  • 在132例给药前样本中,控制错误发现率后37种内源性代谢物与白消安清除率显著相关(<0.05)。
  • LASSO回归从841种代谢物中筛选出13种与白消安清除率主要相关的代谢物。
  • 基于13种代谢物及性别的普通最小二乘线性预测模型应用于96例提前2周样本时,解释40%的白消安清除率变异(校正R2=0.40)。
  • 通路富集分析发现18条通路与白消安清除率相关,排名前两位的是赖氨酸降解和类固醇生物合成,与单因素分析结果一致。

临床怎么用

  • 临床可在白消安给药前利用血浆代谢组学模型预测清除率,辅助个体化剂量决策。
  • 研究者建议该药物代谢组学方法优先于白消安试验剂量或药物基因组学用于指导给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intravenous busulfan doses are often personalized to a target plasma exposure (targeted busulfan) using an individual's busulfan clearance (BuCL). We evaluated whether BuCL could be predicted by a predose plasma panel of 841 endogenous metabolomic compounds (EMCs). In this prospective cohort of 132 hematopoietic cell transplantation (HCT) patients, all had samples collected immediately before busulfan administration (preBU) and 96 had samples collected 2 weeks before busulfan (2-week-preBU). BuCL was significantly associated with 37 EMCs after univariate linear regression analysis and controlling for false discovery (< 0.05) in the 132 preBU samples. In parallel, with preBU samples, we included all 841 EMCs in a least absolute shrinkage and selection operator-penalized regression which selected 13 EMCs as predominantly associated with BuCL. Then, we constructed a prediction model by estimating coefficients for these 13 EMCs, along with sex, using ordinary least-squares. When the resulting linear prediction model was applied to the 2-week-preBU samples, it explained 40% of the variation in BuCL (adjusted R2 = 0.40). Pathway enrichment analysis revealed 18 pathways associated with BuCL. Lysine degradation followed by steroid biosynthesis, which aligned with the univariate analysis, were the top two pathways. BuCL can be predicted before busulfan administration with a linear regression model of 13 EMCs. This pharmacometabolomics method should be prioritized over use of a busulfan test dose or pharmacogenomics to guide busulfan dosing. These results highlight the potential of pharmacometabolomics as a precision medicine tool to improve or replace pharmacokinetics to personalize busulfan doses.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. McCune JS, Navarro SL, Baker KS, et al. Prediction of Busulfan Clearance by Predose Plasma Metabolomic Profiling. Clin Pharmacol Ther. 2022. PMID: 36369996. doi:10.1002/cpt.2794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。